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Abstract
Genetic association studies have revealed a correlation between DNA variations in genes
encoding factors of the hemostatic system and thrombosis-related disease. Certain var‐
iant alleles of these genes that affect either gene expression or function of encoded protein
are known to be genetic risk factors for thrombophilia. The chapter presents the current
genetics and molecular biology knowledge of the most important DNA polymorphisms
in thrombosis-related genes encoding coagulation factor V (FV), coagulation factor II
(FII), coagulation factor XII (FXII), coagulation factor XIII A1 subunit (FXIIIA1), 5,10-
methylene tetrahydrofolate reductase (MTHFR), serpine1 (SERPINE1), angiotensin I-con‐
verting enzyme (ACE), angiotensinogen (AGT), integrin A2 (ITGA2), plasma
carboxypeptidase B2 (CPB2), platelet glycoprotein Ib α polypeptide (GP1BA), thrombo‐
modulin (THBD) and protein Z (PROZ). The molecular detection methods of each DNA
polymorphism is presented, in addition to the current knowledge regarding its influence
on thrombophilia and related thrombotic events, including stroke, myocardial infarction,
deep vein thrombosis, spontaneous abortion, etc. In addition, best thrombosis prevention
strategies with a combination of genetic counseling and molecular testing are discussed.
Keywords: Thrombophilia, coagulation factors, genetic association, DNA polymor‐
phisms, molecular analysis
1. Introduction
Thrombosis is a common underlying pathological event of venous thromboembolism,
ischemic stroke and ischemic heart disorder. It is well established that all three diseases are
associated with a major global burden [1, 2]. Thrombophilia (a Greek composite word
including “thrombos” meaning clot and “philia” meaning friendship) is a condition where
individual susceptibility to thrombotic disease due to deregulation of the hemostatic system
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is known to be influenced by several hereditary and lifestyle-related factors [3–5]. Genetic
association studies have revealed a correlation between DNA variations in genes encoding
factors of the hemostatic system and thrombosis-related disease [6–10].
Certain variant alleles of these thrombosis-associated genes that affect either gene expression
or function of encoded protein are known to be genetic risk factors for thrombophilia. The
genetic variants are found in genes involved in coagulation, fibrinolysis, platelet activity and
other functions related to thrombosis [4, 9, 11]. Most of these are single-nucleotide polymor‐
phisms (SNPs) and affect hemostatic mechanisms in a quantitative or in a qualitative manner
[9, 11]. Primary and secondary prevention of death and disability incidence due to thrombotic
events may be effected through optimized anticoagulant treatment at individual patient level.
This chapter will discuss the current molecular biology and genetics knowledge of the most
important DNA polymorphisms in thrombosis-related genes. In addition, best thrombosis
prevention strategies with a combination of genetic counseling and molecular testing will be
discussed.
2. Coagulation and thrombosis-related factors
Coagulation is a complex multienzymatic cascade by which fibrin is produced forming the
basis of a clot. Thrombosis involves an imbalance of coagulation and fibrinolysis, which also
includes formation and degradation of extracellular matrix (ECM).
The most essential components of the coagulation and fibrinolysis systems are associated with
the endothelial cell membrane, including tissue factor (TF), thrombin and urokinase receptors.
They become exposed when vessels are injured and when platelets are bound to them at early
stages of either coagulation or inflammation. Consequently, platelets release vascular endo‐
thelial growth factor (VEGF) and other growth factors into the circulation, thus promoting
angiogenesis and attracting inflammatory cells to the site of injury [12]. In addition, platelets
also contain hemostatic factors that regulate the extent of tissue repair and inhibit vasculari‐
zation, such as serpine1, previously known as plasminogen activator inhibitor-1 (PAI-1) [12].
The coagulatory cascade is artificially divided based on in vitro testing in the intrinsic or contact
pathway and the extrinsic or tissue factor (TF) pathway. The two pathways interfere since both
thrombin and TF may activate coagulation factor IX (FIX) [12].
3. Tissue factor pathway
TF is expressed constitutively on subendothelial fibroblasts and smooth muscle cells which
are exposed to blood only upon vascular damage. Therefore, TF acts as the physiological
initiator of coagulation [13]. In addition, TF is expressed on peripheral blood monocytes and
on vascular endothelia after exposure to inflammatory or activating stimuli, such as endotoxin.
TF is a transmembrane glycoprotein with an extracellular ligand-binding domain that interacts
with coagulation factor VII in both its inactive and active forms (FVII/FVIIa) [14]. When TF-
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expressing cells in extravascular sites come in contact with plasma, a complex of TF with the
circulating FVII is formed on the cell surface, which is further activated to FVIIa by limited
proteolysis, producing activated coagulation factor X (FXa) and thrombin and leading to
coagulation. The function of TF is kept at appropriate levels through TF pathway inhibitor
(TFPI), a protease inhibitor constitutively released from endothelia. TFPI interacts with
circulating FXa and the TFPI/FXa complex binds to the TF/FVIIa complex down-regulating
TF-induced quaternary complex of Ca2+ and coagulation factors VIIIa, IXa and X [15].
In addition to its hemostatic role, TF is also involved in normal embryonic angiogenesis
through the induction of vascular endothelial growth factor (VEGF) and the secretion up-
regulation of urokinase plasminogen activator receptor [16–18]. Both TF and VEGF are
stimulated by hypoxia through different pathways [19, 20].
4. Thrombin pathway
Thrombin plays a central role in coagulation, since it is the most effective agonist for platelet
activation and leads to the formation of the fibrin clot by activating various zymogens and
cofactors, including fibrinogen, coagulation factors XIII, V and VIII, platelet membrane GPV,
protein S and protein C [21]. Much like TF, thrombin may promote angiogenesis through
different pathways and independently of fibrin generation.
Thrombin also enhances the migratory potential of endothelia through basement membranes
by activating gelatinase A (matrix metalloprotenase-2, MMP-2), which degrades collagen IV
and releases tissue plasminogen (t-PA) and PAI-1 [22–25]. In addition, thrombin activates
platelets, leading to their aggregation and release of numerous pro- and anti-angiogenic factors.
Furthermore, angiogenesis is inhibited by the prothrombin kringle 2 domain as well as two
prothrombin fragments (F1 and F2) generated during activation of thrombin [26, 27].
Thrombin inhibits dissolution of clots and modulates fibrinolysis through activation of
thrombin activatable fibrinolysis inhibitor (TAFI). TAFI cleaves certain C-terminal lysine
residues from fibrin, thereby preventing plasminogen, plasmin and t-PA from binding to fibrin
[28].
Thrombin forms a complex with thrombomodulin, an endothelial cell membrane protein,
leading to the activation of protein C. Consequently, activated protein C cleaves non-platelet-
associated activated coagulation factors V and VII (FVa and FVIIa), thus down-regulating
thrombin formation by inactivating the prothrombinase complex as well as the quaternary
complex of Ca2+ and coagulation factors VIIIa, IXa and X. In addition to its anticoagulant role,
thrombomodulin reduces fibrinolysis by activating TAFI in plasma [29]).
5. Fibrinogen, cross-linked fibrin and fibrinolysis
Fibrinogen plays a critical role in hemostasis. Following activation by thrombin, fibrinogen is
subsequently cleaved to monomers of fibrin that are rapidly combined to form a fibrin matrix.
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In addition, thrombin activates coagulation factor XIII (FXIII) that converts soluble fibrin into
an insoluble polymer of fibrin. Activated FXIII also prevents fibrinolysis by linking α2-plasmin
inhibitor to fibrin [30].
The fibrin gel promotes angiogenesis and cell growth, by providing a provisional matrix,
enriched in growth factors which are protected from degradation, such as VEGF and insulin-
like growth factor-1 [31, 32]. Furthermore, the fibrin gel provides a surface suitable for the
prothrombinase assembly, a function platelets perform in intravascular clotting.
The provisional fibrin matrix undergoes remodeling and is transformed into mature connec‐
tive tissue stroma, which in its constituent elements resembles the stroma of healing wounds
[33, 34]. There is a balance between deposition of fibrin gel from clotting activation and its
dissolution through activation of fibrinolysis [34]. Fibrinolytic activity depends on the balance
between several factors including coagulation XIIa (FXIIa), which converts plasminogen to
plasmin, plasminogen activators (PA) and their inhibitors, such as PAI-1 and α2-antiplasmin.
6. Angiogenesis
Angiogenesis (vascularization) involves a sequence of key events which include focal detach‐
ment of endothelial cells from the basement membrane, localized proteolytic degradation of
the basement membrane and ECM invasion, leading to capillary tube formation and vascular
remodeling [35]. Hemostatic mechanisms may influence angiogenesis directly or indirectly
through a number of different pathways, involving the release of pro-angiogenic and anti-
angiogenic factors from activated platelets. These angiogenesis-related factors, such as tumor
necrosis factor-alpha (TNF-α), promote both formation of fibrin-rich ECM and thrombin
signaling through activation of G-protein-coupled protease-activated receptors on the
endothelial cell surface [21, 36].
7. Thrombosis and cancer
Cancer-related thrombosis represents a complex imbalance of coagulation and fibrinolysis,
also involving the formation and degradation of ECM through interaction of angiogenesis-
related factors [37–40]. Within a tumor, new vessels leak fibrin into the extravascular space
and therefore persistently activate the coagulatory system, both locally and systemically,
producing the clinical appearance of an unhealed wound [12, 41].
The disruption of hemostatic mechanisms is not merely a secondary effect of cancer but it
appears to be a frequent event [41–43]. Sometimes, the activation of coagulation, such as venous
thromboembolism, may even precede the clinical manifestations of cancer [42, 43]. It is well
established that bleeding diathesis and systemic activation of the coagulation cascade con‐
tribute significantly to morbidity and mortality of patients with malignancies [44, 45].
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8. Genetic association studies
Susceptibility in thrombophilia, like in all multifactorial diseases, implicates the interaction
between environmental factors, such as diet or smoking, as well as genetic factors [46]. In the
last couple of decades, population-based genetic association studies have been extensively
investigating DNA polymorphisms in genes putatively involved in multifactorial diseases [39,
40, 46]. Such studies estimate the risk of developing a certain disease by comparing the
frequency of polymorphic genotypes and allele frequencies between patients and matched
healthy controls of the same population. A variant allele or a genotype is associated with
increased risk for a disease when its detected frequency is significantly higher in cases than
controls [47]. A significant association result indicates that the studied DNA polymorphism
tested either directly affects the risk of a certain disease or acts as a genetic marker for a linked
genetic variant that influences risk for that disease [47].
Genetic association studies usually investigate common SNPs in genes of cohorts of individ‐
uals. Over 10 million known SNPs are included in public databases and more of them are
constantly identified. The frequency of the less common variant allele of SNPs in the general
population is at least 1%, while mutations are usually much rarer. Therefore, due to their high
incidence in the population, SNPs are usually very informative [39, 40, 46]. However, genetic
association studies have to be conducted based on certain basic criteria, such as the adequate
number of studied individuals, the gender ratio, age and ethnic compatibility of patients and
healthy controls in order to avoid false positive and false negative results [46, 48]. The observed
genotypic frequencies are considered representative of the population either of patients or
healthy people if they are compatible with the Hardy–Weinberg equilibrium [49]. Highly
significant associations replicated by a number of studies may be a useful tool for the prognosis
and prevention of disease [40, 50].
The spectrum of coagulation and fibrinolysis factors and their respective encoding genes
suggests that a great number of functional DNA polymorphisms might confer a major or minor
risk of thrombosis [4, 7–11, 51, 52]. The most important DNA polymorphisms in thrombosis-
related genes will be discussed, including those encoding (a) coagulation factors, (b) thrombin-
related factors, (c) fibrinolysis-related factors, (d) platelet-adhesion factors and (e) other factors.
A handful of variants in genes encoding for certain factors of the hemostatic system are
positively known to confer a highly significant thrombotic phenotype, such as coagulation
factor V (FV) Leiden, while for other variants there is only some emerging evidence implicating
them in thrombotic disease, such as serpine1 (PAI-1) 4G/5G.
Some of the thrombosis-associated variants are very common in different populations, such as
serpine1 (PAI-1) 4G/5G, which ranges between 42% and 54% worldwide [11]. Other polymor‐
phic variants differ widely among populations, such as thrombomodulin (THBD) -G13A, which
is extremely rare in Caucasians (<1%) and ranges between 8% and 19% in East Asians [53–59].
9. Coagulation factors
FV Leiden is probably the most important hereditary thrombosis-associated factor in Cauca‐
sians, with heterozygotes exhibiting up to 10-fold greater relative risk and Leiden homozy‐
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gotes 50–100-fold greater relative risk of venous thrombosis [60, 61]. FV Leiden is responsible
for 20–25% of isolated thrombotic events and for 40–45% of cases of familial thrombophilia
and fetal loss [3, 62–64]. The FV gene encodes a plasma glycoprotein which is activated by
thrombin/coagulation factor Xa (FXa) and subsequently converted into factor Va (FVa). The
Leiden variant (mutation G1691A) destroys a cleavage site of the anticoagulant-activated
protein C in FVa. This variant has a wide allelic frequency range (1–9%) in European popula‐
tions, while it is virtually absent from non-Caucasian populations [11, 60, 65]. FV Leiden is
thought to have arisen approximately 21,000 to 34,000 years ago in Caucasians [60].
The gene encoding coagulation factor  II  (FII)  or  prothrombin contains  another  common
defect  in  its  3′  untranslated  region  (G20210A).  FII  is  a  plasma  glycoprotein  which  is
activated to thrombin by coagulation factors FXa and FVa. The G20210A mutation is related
to elevated plasma prothrombin levels,  and heterozygotes have up to fourfold increased
risk  of  venous  thrombosis  [66,  67].  The  variant  allele  has  a  frequency  of  1.3–4.5%  in
Caucasian populations [11, 65–67].
A common DNA polymorphism in the gene encoding coagulation factor XII (F12) is C46T. The
prevalence of the thrombosis-related 46T allele ranges between 18% and 37% in various
populations [11, 68]. In the gene F13A1 coding for coagulation factor XIII A1 subunit, a SNP
results in amino acid substitution Val34Leu [69]. There is emerging evidence that the F13 34Leu
allele confers protection against thrombosis [69]. The prevalence of this particular allele varies
considerably between populations ranging between 13% and 28% [11, 69].
9.1. Thrombin-related factors
The prevalence of the thrombin-related SNPs thrombomodulin (THBD) -G13A and protein Z
(PROZ)-A33G is low in Caucasian populations (<1% and 6%, respectively) [11, 54, 70]. Both
SNPs are located in the promoter region of the respective genes and the variant alleles result
in lower levels of gene expression and lower protein production of thrombomodulin and
protein Z. The role of both DNA polymorphisms in susceptibility for thrombosis appears to
be minor.
9.2. Fibrinolysis-related factors
Variants in genes of fibrinolysis-related factors such as serpine1 (also known as plasminogen
activator inhibitor-1, PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI, also known
as plasma carboxypeptidase B2, CPB2) have been shown to have an association with increased
risk of venous thrombosis and myocardial infarction to a diverse extent [56, 71, 72].
A deletion/insertion polymorphism (4G/5G) in the promoter of the serpine1 gene interferes
with regulation of its transcription [72]. The 4G allele binds only an activator, while the 5G
allele binds both a repressor and an activator. Therefore, the presence of the 4G variant results
in higher gene expression, increased inhibition of the plasminogen activators and decreased
plasminogen conversion to plasmin. Several studies have indicated that 4G/4G homozygosity
is a risk factor for deep vein thrombosis, myocardial infarction and miscarriage during
pregnancy [71, 72]. The prevalence of 4G variant in various populations ranges from 31% to
63% [11, 71, 72].
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The effect of the C1040T polymorphism on TAFI (CPB2) function and its modest role in
thrombosis is well established [56, 73]. The C to T substitution at codon 325 leads to a Thr to
Ile change, which has an impact on the thermal stability of the enzyme, resulting in longer
half-life and increased overall antifibrinolytic activity [74]. The prevalence of the 1040T variant
in Caucasians and East Asians (31–40%) is much higher than African populations (11%) [11].
9.3. Platelet-adhesion factors
The role of DNA polymorphisms in genes encoding for platelet-adhesion factors, regarding
the risk for certain thrombotic diseases, remains still uncertain although a minor contribution
may not yet be ruled out. Among the most promising polymorphisms, possibly associated
with risk for cerebrovascular diseases, appear to be C807T in the ITGA2 gene which encodes
integrin A2, also known as platelet glycoprotein Ia and variable number of tandem repeats
(VNTR) in the GP1BA gene which encodes platelet glycoprotein Ibα polypeptide [11, 53, 75].
9.4. Other factors
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme that plays an important role
in  folate  metabolism  [76].  A  C677T  mutation  in  the  MTHFR  gene  involves  an  alanine/
valine change that  renders the protein temperature sensitive and diminishes its  activity,
resulting  in  the  pro-thrombotic  condition  of  hyperhomocysteinemia,  particularly  when
dietary intake of folate is inadequate [8, 77–79]. Homozygotes for the 677T allele account
for 8.5% of the general population in Caucasians, and they are known to have a higher risk
for thrombotic events [11, 80].
Two other factors that are related directly to blood pressure and indirectly to thrombotic events
are angiotensinogen (AGT) and angiotensin-converting enzyme (ACE), two major players in
the rennin–angiotensin system, a circulatory cascade primarily involved in the regulation of
blood pressure and serum electrolytes. AGT is hydrolyzed into angiotensin I by rennin, which
is subsequently converted to potent vasoconstrictor angiotensin II by ACE [81].
Among several DNA polymorphisms in the AGT gene, the only well-studied one is a SNP
at codon 235 because it influences gene expression and therefore has been associated with
hypertension and thrombosis [82–85]. It  involves an amino acid substitution (methionine
to  threonine,  M235T).  The  high  gene  expression  T  allele  has  been  associated  with  in‐
creased hypertension and risk for thrombosis [11, 82–84, 86]. The prevalence of the T variant
is higher in Africans and Asians (78%), while it  is lower in Caucasians ranging between
34% and 55% [11, 86].
ACE activity is mainly determined by the insertion/deletion (I/D) polymorphism of a 287 bp
Alu repeat sequence inside intron 16 of the ACE gene [87]. Homozygotes for the I allele may
display as low as half of the plasma ACE level compared to the homozygotes for the D allele,
whereas the ID heterozygotes display an intermediate level [88]. The presence of the D allele
causes elevation in angiotensin II levels and results in higher blood pressure. The D allele
frequency is more abundant in Europeans (49–58%) than Asians (32–34%) [11].
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10. Molecular detection methodology
Molecular analysis of DNA polymorphisms is usually performed in samples of genomic DNA
extracted from blood, saliva, tissue, hair, semen or any other biological material. DNA testing
of blood or saliva samples is a common practice. As in all occasions of genetic testing, a signed
informed consent has to be obtained from any individual whose DNA would be examined.
The molecular detection methods of each DNA polymorphism depends on several factors
including the nature of the nucleotide variation, the local sequence of the gene, the possible
availability of a restriction enzyme recognizing the sequence of one allele, cost of the detection
method, etc. There are several in-house methods that have been published, while a number of
kits made by private companies are available. In order to study a DNA polymorphism,
molecular geneticists either sequence the gene region of interest or use a method involving
polymerase chain reaction (PCR), followed by analysis of resulting DNA fragments by agarose
gel electrophoresis.
The PCR method usually involves the following: (a) simple use of a pair of primers, if the two
alleles differ in size, as in the case of the ACE I/D polymorphism; (b) PCR followed by restriction
enzyme, if a restriction fragment length polymorphism (RFLP) is present, as in the case of FV
Leiden (G1691A) in which endonuclease TaqΙ is used; (c) an allele-specific primers, when a
common primer is coupled with each allele-specific oligonucleotide (ASO) primer in a separate
PCR, as in the case of the ITGA2 C807T polymorphism.
A typical PCR in total volume of 25–50 μl includes the following steps: (a) an initial denatu‐
ration step at 94°C for 4–5 min; (b) 30–35 cycles of a denaturation step at 94°C for 0.5–1 min,
followed by an annealing step at primer-specific temperature for 0.5–1 min, followed by an
elongation step at 72°C for 0.5–1 min; and (c) a final elongation step at 72°C for 5–7 min. Table
1 presents PCR annealing conditions and primers which may be used for the detection of
functional DNA polymorphisms in thrombosis-related genes, using in-house protocols [11].
Table 2 mentions the expected sizes of DNA fragments viewed by agarose gel electrophoresis
analysis.
Factor (gene
polymorphism)
Annealing
temperature (°C)
Primers Method
Coagulation factors
Coagulation factor II (F2
G20210A)
54 F: 5'-AACAACCGCTGGTATCAAATGG-3' RFLP
R: 5'-GAGCTGCCCATGAATAGCACTG-3'
Coagulation factor V (F5
Leiden)
54 F: 5'-GCA GAT CCC TGG ACA GTC-3' RFLP
R: 5'-ΤGT TAT CAC ACT GGT GCT AA-3'
Coagulation factor (FXII
C46T)
57 F: 5'-ACTTCCAGGACCGCCTTTGGAGGC-3' RFLP
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Factor (gene
polymorphism)
Annealing
temperature (°C)
Primers Method
R: 5'-GTTGACGCCCCGGGGCACCG-3'
Coagulation factor FXIII
A1subunit (F13A1 V34L)
55 F: 5'-ACTTCCAGGACCGCCTTTGGAGGC-3' RFLP
R: 5'-GTTGACGCCCCGGGGCACCG-3'
Fibrinolysis-related factors
Serpine1 (PAI-1 4G/5G) 57 F: 5'- CACAGAGAGAGTCTGGCCACGT-3' RFLP
R: 5'-CCAACAGAGGACTCTTGGTCT-3'
Plasma carboxypeptidase
(CPB2, TAFI C1040T)
57 F: 5'-CACAAAGAAAAACAGATCACACAG-3' RFLP
R: 5'-AAAGCCACCCAATTGTGATT-3'
Thrombin-related factors
Thrombomodulin (THBD
-13G/A)
58 F: 5'-ACCAAGAGATGAAAGAGGGC-3' RFLP
R: 5'-
CGGATCGGCCAGGGCTCGAGTTTATAAAGGCC-3'
Protein Z (PROZ -33A/G) 64 F: 5'-GGGTCCTCTGAGCCTTCACCGTTCATTT-3' RFLP
R: 5'-CAGGCACAACAGACAGGTAAGCCAGATG-3'
Platelet-adhesion factors
Intergin A2 (ITGA2, GPIA
C807T)
56 COMMON: 5'-
GACAGCCCATTAATAAATGTCTCCTCTG-3'
ASO
C: 5'-CCTTGCATATTGAATTGCTACG-3'
T: 5'-CCTTGCATATTGAATTGCTACA-3'
Platelet glycoprotein Iba
(GPIBA VNTR)
63 F: 5'-ACACTTCACATGGACTCCAT--3' VNTR
R: 5'-GGGTCATTTCTGGAGCTCTC--3'
Other factors
Methylenetetrahydrofolate
reductase(MTHFR C677T)
57 F: 5'-TGAAGGAGAAGGTGTCTGCGGGA-3' RFLP
R: 5'-AGGACGGTGCGGTGAGAGTG-3'
Angiotensin I-converting
enzyme (ACE I/D)
60 F: 5'-CTGGAGACCACTCCCATCCTTTCT-3' PCR (I or D
is amplified)R: 5'-GATGTGGCCATCACATTCGTCAGAT-3'
F1: 5'-TGGGACCACAGCGCCCGCCACTAC-3' ASO (only I
is amplified)R1: 5'-TCGCCAGCCCTCCCATGCCCATAA-3'
Angiotensinogen (AGT
M235T)
59 F: 5'-CAGGGTGCTGTCCACACTGGACCCC-3' RFLP
R: 5'-CCGTTTGTGCAGGGCCTGGCTCTCT-3'
RFLP: restriction fragment length polymorphism; ASO: allele-specific oligonucleotide; VNTR: variable number tandem
repeats.
Table 1. Conditions and primers which may be used for molecular detection of functional polymorphisms associated
with thrombophilia.
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Factor
(gene polymorphism)
Method Enzyme
(Temperature, °C)
DNA fragments
of normal
allele (bp)
DNA fragments
of variant
allele (bp)
Coagulation factors
Coagulation factor II
(F2 G20210A))
RFLP TaqI (65) 98 + 10 108
Coagulation factor V
(F5 Leiden)
RFLP TaqI (65) 157 + 18 175
Coagulation factor
(FXII C46T))
RFLP HgaI (37) 369 247 + 122
Coagulation factor FXIII
A1subunit (F13A1 V34L)
RFLP HhaI (37) 94 + 20 114
Fibrinolysis-related factors
Fibrinolysis-related factors
Serpine 1 (PAI-1 4G/5G)
RFLP BslI (37) 77 + 22 99
Plasma carboxypeptidase
(CPB2, TAFI C1040T)
RFLP SpeI (37) 245 + 118 363
Thrombin-related factors
Thrombomodulin
(THBD -13G/A)
RFLP StuI (37) 259 235 + 24
Protein Z (PROZ -33A/G) RFLP HhaI (37) 272 157 + 115
Platelet-adhesion factors
Intergin A2
(ITGA2, GPIA C807T))
ASO 148 148
Platelet glycoprotein Iba
(GPIBA VNTR)
VNTR 315, 237, 198 276
Other factors
Methylenetetrajydrofolate
reductase (MTHFR C677T)
RFLP Hinf1 (37) 198 176 + 22
Angiotensin-converting
enzyme (ACE I/D)
A ASO 190 490
Angiotensinogen(AGT M235T) RFLP TthIII (37) 165 141 + 24
RFLP: restriction fragment length polymorphism; ASO: allele-specific oligonucleotide; VNTR: variable number tandem
repeats.
Table 2. DNA fragments observed after agarose gel electrophoresis.
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11. Prevention of thrombosis
Individual susceptibility to thrombotic diseases, including venous thromboembolism,
ischemic stroke and ischemic heart disorder, is known to be influenced by genetic factor in
addition to lifestyle as reported in earlier studies [1–5, 10]. Prevention of idiopathic thrombosis
is imperative, since it is very common and life-threatening [89–91]. Genetic counseling and
presymptomatic DNA testing is especially important for people with a positive family history
of thrombophilia. Several studies have indicated that pretest genetic counseling would be
helpful in reducing anxiety and confusion about thrombophilia facts [10, 67, 92, 93]. Geneticists
may play a significant role in the prevention of thrombophilia if, during their routine collection
of family history data during counseling for other diseases, they recognize the individuals at
risk for thrombosis and inform them about preventive measures, including the available
molecular tests.
The ability to routinely detect the inherited genetic predisposition for thrombosis (either
mutation- or disease-associated polymorphisms) may significantly contribute to early
diagnosis and make possible early intervention and prevention of thrombotic incidents.
Individuals with increased risk for thrombophilia should best be referred to hematologists
who may advise some of them to receive preventive anticoagulant therapy. Particularly,
women at risk for thrombosis should consult a hematologist before taking contraceptive pills,
as well as in case of pregnancy. The optimal management of asymptomatic at risk individuals
remains unclear, but it is generally agreed that thromboprophylaxis should be provided, at
least in high-risk periods such as during surgery or pregnancy [10, 94–104].
Molecular diagnostics and prevention of thrombophilia will be greatly benefited when the
relative contribution of each thrombosis-related DNA polymorphism to vascular disease is
better understood, possibly with the aid of large-scale epidemiological studies. Only then, a
population-wide screening might be warranted for preventative purposes. At this stage, initial
information about the prevalence of major DNA polymorphisms is recommended for each
population in order to shape local health policies for prevention of thrombosis by identification
of individuals at risk.
As an example, in southern and eastern Europeans prevention of thrombophilia may be
significantly effected by studying genetic variants FV Leiden and FII G20210A since they both
appear to be found in relatively high frequencies and to be major susceptibility factors for
thromboembolic incidents in these populations [55, 67, 105–110]. A study in Greeks indicated
that the combination of genetic counseling and molecular testing for these two common
thrombophilia may increase up to fivefold the identification of at risk individuals compared
to population-wide screening and has a significant impact on the prevention of thromboem‐
bolic incidents [66].
As genetic testing becomes a routine approach, it is expected that it will be extensively used
both in hospital and community preventive medicine. Accordingly, it may be envisaged that
thrombophilia, which is currently such a major global burden, shall be routinely preventable
in the future with the aid of genetic testing and proper anticoagulant treatment, thus safe‐
guarding the life and health status of asymptomatic individuals at risk.
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